These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Intravitreous injection of bevacizumab, tissue plasminogen activator, and gas in the treatment of submacular hemorrhage in age-related macular degeneration. Guthoff R; Guthoff T; Meigen T; Goebel W Retina; 2011 Jan; 31(1):36-40. PubMed ID: 20921929 [TBL] [Abstract][Full Text] [Related]
23. Retrospective study of an as required dosing regimen of intravitreal bevacizumab in neovascular age-related macular degeneration in an Australian population. Luu ST; Gray T; Warrier SK; Patel I; Muecke JS; Casson R; Gilhotra JS Clin Exp Ophthalmol; 2010 Oct; 38(7):659-63. PubMed ID: 20456433 [TBL] [Abstract][Full Text] [Related]
24. Functional recovery after intravitreal bevacizumab treatments for idiopathic choroidal neovascularization in young adults. Wang F; Wang W; Yu S; Wang W; Lu F; Xu F; Hu W; Jiang Y; Wu Y; Wang H; Xu X; Sun X Retina; 2012 Apr; 32(4):679-86. PubMed ID: 22105501 [TBL] [Abstract][Full Text] [Related]
25. Intravitreal bevacizumab for choroidal neovascularization secondary to inflammation. Wolf A; Thurau S; Kook D; Hoeing A; Priglinger S; Kampik A; Haritoglou C Acta Ophthalmol; 2010 Nov; 88(7):e295-6. PubMed ID: 19860782 [No Abstract] [Full Text] [Related]
26. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment. Fong KC; Kirkpatrick N; Mohamed Q; Johnston RL Clin Exp Ophthalmol; 2008 Nov; 36(8):748-55. PubMed ID: 19128380 [TBL] [Abstract][Full Text] [Related]
27. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML Retina; 2007; 27(4):439-44. PubMed ID: 17420695 [TBL] [Abstract][Full Text] [Related]
28. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration. Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764 [TBL] [Abstract][Full Text] [Related]
29. Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis. Schadlu R; Blinder KJ; Shah GK; Holekamp NM; Thomas MA; Grand MG; Engelbrecht NE; Apte RS; Joseph DP; Prasad AG; Smith BT; Sheybani A Am J Ophthalmol; 2008 May; 145(5):875-8. PubMed ID: 18321466 [TBL] [Abstract][Full Text] [Related]
30. Intravitreal bevacizumab for subfoveal choroidal neovascularization associated with pattern dystrophy. Parodi MB; Iacono P; Cascavilla M; Zucchiatti I; Kontadakis DS; Bandello F Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4358-61. PubMed ID: 20375343 [TBL] [Abstract][Full Text] [Related]
31. Intravitreal bevacizumab treatment of bilateral peripapillary choroidal neovascularization from optic nerve head drusen. Knape RM; Zavaleta EM; Clark CL; Khuddus N; Peden MC J AAPOS; 2011 Feb; 15(1):87-90. PubMed ID: 21397813 [TBL] [Abstract][Full Text] [Related]
32. [Intravitreal bevacizumab for choroidal neovascularization due to pathological myopia]. Dithmar S; Schaal KB; Höh AE; Schmidt S; Schütt F Ophthalmologe; 2009 Jun; 106(6):527-30. PubMed ID: 18688616 [TBL] [Abstract][Full Text] [Related]
33. Intravitreal bevacizumab for inflammatory choroidal neovascularization: results from the Pan-American Collaborative Retina Study Group at 24 months. Arevalo JF; Adan A; Berrocal MH; Espinoza JV; Maia M; Wu L; Roca JA; Quiroz-Mercado H; Ruiz-Moreno JM; Serrano MA; Retina; 2011 Feb; 31(2):353-63. PubMed ID: 20890239 [TBL] [Abstract][Full Text] [Related]
35. Short-term safety and efficacy of a single intravitreal bevacizumab injection for the management of polypoidal choroidal vasculopathy. Song JH; Byeon SH; Lee SC; Koh HJ; Kwon OW Ophthalmologica; 2009; 223(2):85-92. PubMed ID: 19023226 [TBL] [Abstract][Full Text] [Related]
36. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series. Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926 [TBL] [Abstract][Full Text] [Related]